KeyBanc Reaffirms Overweight on Danaher, Cites Durable Bioprocess Momentum
KeyBanc has reiterated an Overweight rating on Danaher Corporation and set a $310 price target, citing sustained bioprocess growth, improving diagnostics and life-science end markets, and strong cash generation. The target implies roughly 38% upside from the prevailing share price. Danaher’s latest quarterly results beat expectations, and managemen…